NI201500128A - 3- pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante - Google Patents

3- pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante

Info

Publication number
NI201500128A
NI201500128A NI201500128A NI201500128A NI201500128A NI 201500128 A NI201500128 A NI 201500128A NI 201500128 A NI201500128 A NI 201500128A NI 201500128 A NI201500128 A NI 201500128A NI 201500128 A NI201500128 A NI 201500128A
Authority
NI
Nicaragua
Prior art keywords
onas
oxazolidin
pyrimidin
inhibitors
formula
Prior art date
Application number
NI201500128A
Other languages
English (en)
Inventor
Raymond Caferro Thomas
Chen Zhuoliang
Shin Cho Young
Q Costales Abran
Roy Levell Julian
Liu Gang
R Manning James
Sendzik Martin
Shafer Cynthia
David Shultz Michael
Sutton James
Wang Yaping
Zhao Qian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NI201500128A publication Critical patent/NI201500128A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se dirige a la fórmula (I): o una sal farmacéuticamente aceptable del mismo, en donde R1, R2a, R2b y R3-R7 se definen en la presente. La invención también se refiere a composiciones que contienen un compuesto de la fórmula (I) y al uso de tales compuestos en la inhibición de proteínas IDH mutantes que tienen una actividad neomórfica. La invención se refiere además al uso de un compuesto de la Fórmula (I) en el tratamiento de enfermedades o trastornos asociados con tales proteínas IDH mutantes incluyendo pero sin limitar a, trastornos de proliferación celular como el cáncer.
NI201500128A 2013-03-14 2015-09-09 3- pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante NI201500128A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361783210P 2013-03-14 2013-03-14
US201361892131P 2013-10-17 2013-10-17

Publications (1)

Publication Number Publication Date
NI201500128A true NI201500128A (es) 2015-11-18

Family

ID=50382516

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500128A NI201500128A (es) 2013-03-14 2015-09-09 3- pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante

Country Status (29)

Country Link
US (4) US9434719B2 (es)
EP (1) EP2970240B1 (es)
JP (1) JP6387360B2 (es)
KR (1) KR20150131224A (es)
CN (1) CN105263929B (es)
AP (1) AP2015008707A0 (es)
AR (1) AR095311A1 (es)
AU (1) AU2014229313B2 (es)
BR (1) BR112015023412A8 (es)
CA (1) CA2903979A1 (es)
CL (1) CL2015002472A1 (es)
CR (1) CR20150491A (es)
CU (1) CU20150119A7 (es)
DO (1) DOP2015000240A (es)
EA (1) EA028033B1 (es)
ES (1) ES2665619T3 (es)
GE (1) GEP201706699B (es)
HK (1) HK1213251A1 (es)
IL (1) IL240972A0 (es)
MX (1) MX355945B (es)
NI (1) NI201500128A (es)
PE (1) PE20151939A1 (es)
PH (1) PH12015502018A1 (es)
SG (1) SG11201507063YA (es)
TN (1) TN2015000392A1 (es)
TW (1) TW201444831A (es)
UY (1) UY35470A (es)
WO (1) WO2014141104A1 (es)
ZA (1) ZA201506452B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CA2903569C (en) 2013-03-14 2023-04-11 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides and their use as inhibitors of cathepsin c
MX355945B (es) 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
ES2788848T3 (es) 2013-09-06 2020-10-23 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
KR102510588B1 (ko) 2014-09-12 2023-03-17 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 스피로사이클릭 억제제
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
CU24509B1 (es) 2015-03-10 2021-05-12 Aurigene Discovery Tech Ltd Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores
KR20170129802A (ko) 2015-03-10 2017-11-27 아두로 바이오테크, 인코포레이티드 ＂인터페론 유전자의 자극인자＂-의존적 신호전달을 활성화하는 조성물 및 방법
JP6473270B2 (ja) 2015-07-27 2019-02-20 イーライ リリー アンド カンパニー ７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物及び変異体ｉｄｈ１阻害剤としてのそれらの使用
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
HRP20220436T1 (hr) 2015-11-03 2022-05-27 Janssen Biotech, Inc. Protutijela koja se specifično vežu na pd-1 i njihove uporabe
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
CN107216312B (zh) 2016-03-22 2023-08-01 上海海和药物研究开发股份有限公司 一种具有突变型idh抑制活性的化合物、其制备方法及用途
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US10800760B2 (en) 2017-05-31 2020-10-13 Nantbio, Inc. Trk inhibition
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
EA202090536A1 (ru) 2017-10-11 2020-07-22 Ориджен Дискавери Текнолоджис Лимитед Кристаллические формы 3-замещенного 1,2,4-оксадиазола
EA202090746A1 (ru) 2017-11-03 2020-08-17 Ориджен Дискавери Текнолоджис Лимитед Двойные ингибиторы путей tim-3 и pd-1
WO2019087092A1 (en) 2017-11-06 2019-05-09 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
CN110156786B (zh) * 2018-02-13 2022-06-03 青煜医药研发(上海)有限公司 嘧啶并环化合物及其制备方法和应用
CN110407855A (zh) * 2018-04-26 2019-11-05 上海嗣新生物科技有限公司 2-氨基嘧啶啶衍生物及其制备方法和用途
ES2929406T3 (es) 2018-05-21 2022-11-29 Nerviano Medical Sciences Srl Compuestos de piridonas heterocondensadas y su uso como inhibidores de IDH
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
EP3836932A2 (en) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Method for treating pancreatic cancer
CN109659001B (zh) * 2018-12-18 2023-08-04 延安大学 一种防癌监管系统及方法
US20220119354A1 (en) 2019-02-01 2022-04-21 Fmc Corporation Diamino-substituted pyridines and pyrimidines as herbicides
CN115838369A (zh) 2019-03-19 2023-03-24 株式会社沃若诺伊 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物
SG11202112158YA (en) * 2019-05-03 2021-12-30 Praxis Prec Medicines Inc Kcnt1 inhibitors and methods of use
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
CN110964005A (zh) * 2019-12-16 2020-04-07 武汉九州钰民医药科技有限公司 一种Alpelisib的制备工艺
CN111057051A (zh) * 2019-12-16 2020-04-24 武汉九州钰民医药科技有限公司 PI3K抑制剂Alpelisib的新合成方法
CN111362925B (zh) * 2020-05-26 2020-09-08 北京鑫开元医药科技有限公司 一种4-嘧啶甲酰胺类化合物、药物组合物、制备方法及应用
EP4186525A4 (en) 2020-07-21 2024-04-03 Daiichi Sankyo Company, Limited COMBINATION DRUG OF TEMOZOLOMIDE AND MUTATED IDH1 ENZYME INHIBITOR
EP4210766A1 (en) * 2020-09-14 2023-07-19 Totus Medicines Inc. Therapeutic conjugates
AU2022294860A1 (en) * 2021-06-15 2024-01-25 Wigen Biomedicine Technology (shanghai) Co., Ltd. Idh mutant inhibitor and use thereof

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB581334A (en) 1943-09-29 1946-10-09 Francis Henry Swinden Curd New pyrimidine compounds
JPS4921149B1 (es) 1970-12-28 1974-05-30
JPS4921148B1 (es) 1970-12-28 1974-05-30
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
US4994386A (en) 1987-07-13 1991-02-19 Pharmacia Diagnostics, Inc. Production of HBLV virus in the HSB-2 cell line
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
EP0330263A1 (en) 1988-02-25 1989-08-30 Merck & Co. Inc. Piperazinylalkylpyrimidines as hypoglycemic agents
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
EP0489925B1 (en) 1990-07-03 1996-06-12 Mitsui Petrochemical Industries, Ltd. Pyrimidine compound and pharmaceutically acceptable salt thereof
US5786355A (en) 1995-04-13 1998-07-28 Taiho Pharmaceutical Co., Ltd. 4,6-diarylpyrimidine derivatives and salts thereof
JP3734907B2 (ja) 1996-12-19 2006-01-11 富士写真フイルム株式会社 現像処理方法
US6251900B1 (en) 1997-07-24 2001-06-26 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and antitumor agent containing the same as active ingredient
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6150362A (en) 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
PT930302E (pt) 1998-01-16 2003-07-31 Hoffmann La Roche Derivados de benzo-sulfona
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
EP1087963B1 (en) 1998-06-19 2004-08-25 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CA2359680A1 (en) 1999-01-22 2000-07-27 David M. Armistead Kinase inhibitors
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
WO2001000207A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
EP1194152A4 (en) 1999-06-30 2002-11-06 Merck & Co Inc SIN KINASE INHIBITOR COMPOUNDS
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
AU777735B2 (en) 1999-07-15 2004-10-28 Pharmacopeia, Inc. Bradykinin B1 receptor antagonists
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
CA2400447C (en) 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
NZ521068A (en) 2000-03-29 2005-04-29 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
JP3649395B2 (ja) 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
NZ522217A (en) 2000-04-28 2004-04-30 Tanabe Seiyaku Co Cyclic compounds
EP1296977A1 (en) 2000-06-23 2003-04-02 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
KR100816769B1 (ko) 2000-09-06 2008-03-26 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 글리코겐 합성효소 키나아제 3의 억제제
US6638926B2 (en) 2000-09-15 2003-10-28 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SE0004053D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
CN100436452C (zh) 2000-12-21 2008-11-26 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2002064096A2 (en) 2001-02-16 2002-08-22 Tularik Inc. Methods of using pyrimidine-based antiviral agents
EP1395561A1 (en) 2001-05-25 2004-03-10 Boehringer Ingelheim Pharmaceuticals Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
US6603000B2 (en) 2001-07-11 2003-08-05 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis for heteroarylamine compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EP1485380B1 (en) 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines as inhibitors of protein kinases
AU2003225800A1 (en) 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
ES2289279T3 (es) 2002-03-15 2008-02-01 Vertex Pharmaceuticals Incorporated Composiciones utiles como inhibidores de proteinquinasas.
ATE466580T1 (de) 2002-03-15 2010-05-15 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
EP1546115A4 (en) 2002-09-27 2010-08-04 Merck Sharp & Dohme SUBSTITUTED PYRIMIDINES
AU2003288925A1 (en) 2002-10-08 2004-05-04 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
WO2004048365A1 (en) 2002-11-21 2004-06-10 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
JP2006521357A (ja) 2003-03-24 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
AU2004230928B2 (en) 2003-04-09 2010-12-02 Exelixis, Inc. Tie-2 modulators and methods of use
EP1651619A1 (en) 2003-07-15 2006-05-03 Neurogen Corporation Substituted pyrimidin-4-ylamin analogues as vanilloid receptor ligands
CA2531619A1 (en) 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
JP2007532669A (ja) 2004-04-13 2007-11-15 イカジェン インコーポレイテッド カリウムイオンチャネル調節剤としての多環式ピリミジン
GB0415367D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
MY145822A (en) 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
AU2005317176A1 (en) 2004-12-13 2006-06-22 Neurogen Corporation Piperazinyl-pyridine analogues
AU2005322328A1 (en) 2004-12-13 2006-07-06 Neurogen Corporation Substituted biaryl analogues
US7300931B2 (en) 2004-12-28 2007-11-27 Kinex Pharmaceuticals, Llc Compositions for treating cell proliferation disorders
JP2008528506A (ja) 2005-01-19 2008-07-31 ニューロジェン・コーポレーション ヘテロアリール置換ピペラジニル−ピリジン類縁体
CA2599320A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
JP2008536950A (ja) 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
AU2007204208A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
KR20080091814A (ko) 2006-01-20 2008-10-14 쉐링 코포레이션 지질혈증장애의 치료를 위한 니코틴산 수용체 효능제로서의헤테로사이클
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PE20071321A1 (es) 2006-01-20 2007-12-29 Schering Corp Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
EP1981880B1 (en) 2006-01-27 2010-02-24 F.Hoffmann-La Roche Ag Use of 4-imidazole derivatives for cns disorders
WO2008080937A1 (en) 2006-12-28 2008-07-10 Basf Se 2-substituted pyrimidines i in therapy
AU2008213808B2 (en) 2007-02-06 2011-11-10 Novartis Ag PI 3-kinase inhibitors and methods of their use
US7957951B2 (en) 2007-03-16 2011-06-07 Robert Bosch Gmbh Address translation system for use in a simulation environment
JP2010533158A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物類−９４５
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
BRPI0908049A2 (pt) 2008-03-05 2015-08-11 Novartis Ag Uso de derivados de pririmidina para o tratamento de doenças dependentes de egfr ou de doenças que possuem resistência adquirida a agentes que são direcionados aos membros da família de egfr
MX2010010505A (es) 2008-03-26 2010-10-26 Novartis Ag Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
WO2009120094A2 (en) 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
TW200948362A (en) 2008-04-09 2009-12-01 Mitsubishi Tanabe Pharma Corp New compounds and their uses
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
KR20110090911A (ko) 2008-10-31 2011-08-10 노파르티스 아게 포스파티딜이노시톨-3-키나아제 (ｐｉ3ｋ) 억제제 및 ｍｔｏｒ 억제제의 조합물
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
JP5747440B2 (ja) 2009-02-06 2015-07-15 住友化学株式会社 ヒドラジド化合物及びその有害生物防除用途
EP2394999B1 (en) 2009-02-06 2014-01-29 Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and medicine
CN108524505A (zh) 2009-03-13 2018-09-14 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
KR20120016247A (ko) 2009-05-19 2012-02-23 다우 아그로사이언시즈 엘엘씨 진균 방제를 위한 화합물 및 방법
WO2011005119A1 (en) 2009-07-07 2011-01-13 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
AR077695A1 (es) 2009-08-04 2011-09-14 Schering Corp Derivados de pirimidina como inhibidores del factor ixa
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
CA2773848A1 (en) 2009-09-09 2011-03-17 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
US20120215788A1 (en) 2009-11-18 2012-08-23 Nokia Corporation Data Processing
JP5967827B2 (ja) * 2009-12-09 2016-08-10 アジオス ファーマシューティカルズ， インコーポレイテッド Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物
GB201004200D0 (en) 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
MX342951B (es) 2010-07-16 2016-10-18 Agios Pharmaceuticals Inc * Composiciones terapeuticamente activas y su metodo de uso.
BR112013007123B1 (pt) 2010-10-01 2021-11-09 Novartis Ag Forma cristalina do sal de monocloridrato de um composto a, seu uso, e composição farmacêutica
AU2011317152C1 (en) 2010-10-18 2016-02-25 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilisation
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
KR20140063509A (ko) 2011-02-11 2014-05-27 다나-파버 캔서 인스티튜트 인크. 과오종 종양 세포의 억제 방법
CN102827073A (zh) * 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US20140213583A1 (en) 2011-09-01 2014-07-31 Novartis Ag PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone
MX342326B (es) * 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
WO2013052395A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
BR112014024552A2 (pt) 2012-04-02 2017-09-19 Cytokinetics Inc método para aprimorar a função do diafragma em um paciente que necessite do mesmo; método para aumentar a função, atividade, eficiência, sensibilidade ao cálcio ou tempo de fadiga do músculo esquelético no diafragma de um paciente que necessite do mesmo e método para aumentar a função, atividade, eficiência, força, sensibilidade ao cálcio ou tempo de fadiga de uma fibra muscular esquelética do diafragma.
EP2836590A4 (en) 2012-04-11 2016-04-13 Cytokinetics Inc METHOD FOR IMPROVING THE RESISTANCE TO SKELETON MUSCULAR FEEDING
WO2013173283A1 (en) 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
RU2014150494A (ru) 2012-05-30 2016-07-20 Ф. Хоффманн-Ля Рош Аг Пирролидиногетероциклы
MX2014014969A (es) 2012-06-06 2015-03-13 Novartis Ag Combinacion de un inhibidor de la 17-alfa-hidroxilasa (c17,20-liasa) y un inhibidor especifico de la pi-3k para tratar una enfermedad tumoral.
EP2885003B1 (en) 2012-08-16 2021-09-29 Novartis AG Combination of pi3k inhibitor and c-met inhibitor
JP6267213B2 (ja) 2012-10-23 2018-01-24 ノバルティス アーゲー ５−（２，６−ジ−４−モルホリニル−４−ピリミジニル）−４−トリフルオロメチルピリジン−２−アミンを製造するための改良された方法
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
DK3007689T3 (en) 2013-01-10 2018-06-14 Pulmokine Inc NON-SELECTIVE KINASE INHIBITORS
MX355945B (es) 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN103483345B (zh) 2013-09-25 2016-07-06 中山大学 Pi3k激酶抑制剂、包含其的药物组合物及其应用
CN103694218B (zh) 2013-12-05 2016-04-27 中山大学 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用

Also Published As

Publication number Publication date
PH12015502018A1 (en) 2016-01-11
CR20150491A (es) 2016-01-29
HK1213251A1 (zh) 2016-06-30
KR20150131224A (ko) 2015-11-24
EP2970240A1 (en) 2016-01-20
US9688672B2 (en) 2017-06-27
US10112931B2 (en) 2018-10-30
IL240972A0 (en) 2015-11-30
SG11201507063YA (en) 2015-10-29
CA2903979A1 (en) 2014-09-18
MX355945B (es) 2018-05-07
AR095311A1 (es) 2015-10-07
US9434719B2 (en) 2016-09-06
US20160318915A1 (en) 2016-11-03
UY35470A (es) 2014-10-31
JP6387360B2 (ja) 2018-09-05
US20180051015A1 (en) 2018-02-22
DOP2015000240A (es) 2015-12-15
TN2015000392A1 (en) 2017-01-03
TW201444831A (zh) 2014-12-01
AU2014229313B2 (en) 2016-07-28
ES2665619T3 (es) 2018-04-26
CL2015002472A1 (es) 2016-01-04
MX2015012552A (es) 2016-04-18
CN105263929A (zh) 2016-01-20
AU2014229313A1 (en) 2015-10-01
AP2015008707A0 (en) 2015-09-30
CU20150119A7 (es) 2016-06-29
EP2970240B1 (en) 2018-01-10
EA201591745A1 (ru) 2016-01-29
PE20151939A1 (es) 2016-01-08
JP2016513633A (ja) 2016-05-16
US20140275083A1 (en) 2014-09-18
CN105263929B (zh) 2018-08-28
EA028033B1 (ru) 2017-09-29
WO2014141104A1 (en) 2014-09-18
US20150152093A1 (en) 2015-06-04
BR112015023412A8 (pt) 2018-01-23
BR112015023412A2 (pt) 2017-07-18
ZA201506452B (en) 2016-07-27
GEP201706699B (en) 2017-07-10

Similar Documents

Publication Publication Date Title
NI201500128A (es) 3- pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
NI201400026A (es) 3 - pirimidin - 4 - il - oxazolidin - 2 - onas como inhibidores de la idh mutante.
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
EA202090291A2 (ru) Производные бипиразола в качестве ингибиторов jak
IN2015DN01156A (es)
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201490357A1 (ru) Индазолы
DOP2013000084A (es) Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap)
TR201901886T4 (tr) DNA-PK inhibitörleri.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EA201491356A1 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
MA40076A (fr) Inhibiteurs de syk
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA201390010A1 (ru) Замещенные триазолопиридины
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
EA201491878A1 (ru) Замещенные ксантиновые производные
UY30514A1 (es) Compuestos organicos